# Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>04</td>
<td>Welcome Letter</td>
</tr>
<tr>
<td>05</td>
<td>Membership</td>
</tr>
<tr>
<td>08</td>
<td>Scientific Affairs</td>
</tr>
<tr>
<td>13</td>
<td>Education &amp; Conferences</td>
</tr>
<tr>
<td>18</td>
<td>Webinars</td>
</tr>
<tr>
<td>20</td>
<td>JTO &amp; JTO CRR</td>
</tr>
<tr>
<td>22</td>
<td>IASLC Lung Cancer News</td>
</tr>
<tr>
<td>24</td>
<td>Podcasts</td>
</tr>
<tr>
<td>26</td>
<td>Committees</td>
</tr>
<tr>
<td>30</td>
<td>Patient Advocacy</td>
</tr>
<tr>
<td>33</td>
<td>Corporate Relations</td>
</tr>
<tr>
<td>34</td>
<td>IASLC Foundation, LLC</td>
</tr>
<tr>
<td>39</td>
<td>Financials</td>
</tr>
<tr>
<td>40</td>
<td>IASLC Board of Directors</td>
</tr>
<tr>
<td>41</td>
<td>IASLC Staff</td>
</tr>
</tbody>
</table>
Dear colleagues and friends,

2022 was a mix of old and new for IASLC. We were thrilled to return to in-person events and equally excited to welcome our new CEO Karen Kelly and many wonderful new staff members. It was a year focused on providing as much benefit as possible for our members.

The ups and downs of the pandemic found our team quickly pivoting two planned in-person meetings into virtual ones, and still providing an outstanding experience for our members at TTLC and ELCC. We successfully returned to in-person events with WCLC in August with 3,348 attendees on-site in Vienna and another 1,837 joining us virtually. It was a phenomenal hybrid meeting. During the WCLC, we recognized the IASLC Distinguished Service Awardees and Lectureship Awardees and hosted 5 plenary sessions, 39 education sessions, 15 oral sessions, 14 mini-oral sessions, 18 interactive breakfast sessions, and 8 workshops—including the 2022 CT Screening Symposium: Forefront Advances in Lung Cancer Screening. It was a whirlwind! Participants in our first IASLC STEPS Challenge, a virtual walkathon, stepped out to benefit the lung cancer research grant program. Many found a night of dancing at our foundation gala a great way to increase step counts.

We also successfully hosted the North America Conference on Lung Cancer in Chicago in September, where more than 550 participants from 25 countries, participated in person or remotely, to learn from 6 symposia, nearly 100 posters, and more than 100 abstract presentations. In October, the Asia Conference on Lung Cancer returned as a live and on-demand event. More than 500 delegates from 37 countries, learned from more than 110 speakers.

In 2022, we welcomed our new chief executive officer Dr. Karen Kelly, an internationally recognized and widely published lung cancer expert and former IASLC board member. She stepped down from her roles as a Professor at University of California, Davis, and as thoracic committee chair of SWOG to join the IASLC team full-time in Denver. Her experience and vision significantly enhance the organization. J. Michael Hoehn brought his considerable experience in business and nonprofits when he joined IASLC as the chief operating officer this year. He brings business management, strategic planning, and vision to the organization. In addition, we also added nine new staff members who are all eager to help meet the needs of our members.

Our publications also achieved success in 2022 with the Journal of Thoracic Oncology increasing its impact factor to 20.121, up from 15.069 last year—making it 4th of 66 respiratory journals and 13th of 245 oncology-specific journals. What’s more, the JTO experienced a 1,704% increase in full-text article downloads in 2022.

We hired Dr. Emily Stone, from Australia to take over as Editor-in-Chief of the Journal of Thoracic Oncology Clinical and Research Reports, the IASLC’s open-access companion journal, which publishes a range of manuscripts and was indexed in 2022 on PubMed Central. Dr. Stone took the helm in January 2023. Dr. Stone is a consultant respiratory physician and Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St. Vincent’s Hospital Sydney.

To support our efforts to provide the best value to our membership, we initiated a membership survey, the first since the pandemic. The survey asked members for feedback on member needs and benefits in the post-COVID world. More than 1,100 members from 77 countries shared their feedback. We are reviewing the input and will release a summary of these findings in 2023.

To support and fund emerging research in the field of thoracic lung cancer, the ILCF & IASLC Board of Directors transitioned the foundation to become a wholly owned entity of the IASLC with a new moniker, the IASLC Foundation, LLC. Its mission remains the same—to accelerate the pace of thoracic malignancy research and fund the next generation of lung cancer luminaries. In 2022, the Foundation received $78,426 in individual donations. Please click here for the full list of our 2022 donors. The Foundation awarded 14 research grants totaling $850,000.

This year’s grant recipients represent a diverse group of early-career researchers from around the world. IASLC Research Grants are made possible by donations from individual donors, foundation partners, and pharmaceutical companies and foundations.

Also this year we completed the data analysis for the 9th edition of the TNM Staging System and new recommendations from AJCC/UICC will be available to the public in 2024. For the first time, new data elements such as gene mutations, fusions, alterations, protein expression levels, and other critical tumor characteristics were collected for analysis. Work has already begun on the 10th edition.

And finally, members of our 13 IASLC committees contributed their skills and talents to help move the society forward by publishing multiple manuscripts, atlases, and other resources; supporting early-career and research grant recipients; leading workshops, webinars, surveys, and academies; and sharing the message of the organization with the larger lung and thoracic cancer communities.

As we head into 2023, we will be looking back at the 50-year history of IASLC with plans underway for a retrospective book so our members can appreciate how far we’ve come in the fight against thoracic cancers.

As we begin a new year, we believe this is an exciting time for IASLC as our members make unprecedented scientific advances and disseminate new knowledge to help prevent and treat thoracic malignancies worldwide. We hope you will continue to lend your expertise, knowledge, and enthusiasm to the fight.

Sincerely,

Heather Wakelee, MD
IASLC President

Karen Kelly, MD
IASLC Chief Executive Officer

IASLC ANNUAL REPORT 2022
TOGETHER, WE ARE CONQUERING LUNG CANCER WORLDWIDE

With a diverse multidisciplinary and international membership base, the IASLC is always looking for ways to listen to our members and improve the member experience. Because member feedback is critical to strategic planning initiatives, we conducted our first member survey since the COVID-19 pandemic. We received more than 1,000 responses from 77 countries, which provided critical information we need to plan future initiatives that build additional member value. Survey results will be shared with the membership soon.

IASLC members remain at the forefront of scientific achievement in multiple disciplines, and the IASLC seeks to continue to provide membership services that encourage more achievements in the future.

For more than four decades, IASLC members have led a worldwide movement to advance the mission of conquering thoracic cancers across the globe. In 2022, at events such as the World Conference on Lung Cancer (WCLC), the Asia Conference on Lung Cancer, the North America Conference on Lung Cancer, the IASLC CT Screening Symposium, and the Targeted Therapies of Lung Cancer Meeting, lung cancer specialists accessed the latest research and scientific discoveries in thoracic oncology, allowing them to advance their profession through education and development opportunities.

This year, the IASLC’s focus was on returning to in-person events while also ensuring our colleagues across the globe had virtual access to important content. At WCLC in Vienna, many of our members were able to reconnect face-to-face for the first time since the pandemic and we remain hopeful for increased connections in 2023. Other meetings throughout the year emphasized reconnecting in person, allowing our members to share experiences and important information from their work in the field of thoracic cancer.

Comprising every specialty in lung cancer, IASLC committee members and their contributions are at the heart of the society. As part of our 13 committees, ranging from patient advocacy to scientific committees and more, IASLC committee members continue to contribute their specialized skills and talents to help shape the work of the organization, develop educational content, plan annual meetings, contribute to publications authored by the IASLC, and more.

The IASLC is always looking to improve the member experience and be the hub for education and collaboration for all of our members, regardless of career phase, specialty, or geographic location. As we move into 2023 with a new CEO, we will continue to enhance our value to members with our soon-to-be-released strategic plan.

The IASLC continues to put our members first—so they can go above and beyond for patients—by offering discounted registration fees to meetings and educational events, complimentary access to the Journal of Thoracic Oncology (JTO), and discounted publication fees for the open-access IASLC journal, JTO Clinical and Research Reports (JTO CRR). Another great member benefit is the IASLC Online Member Directory which allows members to directly connect and collaborate. In addition, the IASLC is proud to offer members access to free continuing medical education opportunities, volunteer opportunities, and more.
IASLC MEMBERSHIP BY THE NUMBERS

MEMBERS BY COUNTRY/REGION

NORTH AMERICA
2 countries
43%

LATIN AMERICA
19 countries
6%

AFRICA
13 countries
1%

EUROPE
43 countries
22%

ASIA
28 countries
24%

AUSTRALIA
1 country
4%

TOP 10 COUNTRIES FOR MEMBERSHIP

USA
JAPAN
CHINA
CANADA
AUSTRALIA
UK
BRAZIL
REPUBLIC OF KOREA
INDIA
NETHERLANDS
6,176 MEMBERS TOTAL

MEMBERS BY PRIMARY SPECIALTY

Medical Oncology 32.3%
Thoracic Surgery 13.7%
Other* 14.8%
Pulmonary Medicine 9.5%
Cancer Res./Basic Sciences 6.8%
Radiation Oncology 6.1%
Pathology 5.6%
Advocacy 4.3%
Biotech/Pharm. Industry 3.6%
Diagnostic Radiology 1.7%
Nursing 1.6%

* Other includes: Pharmacy, Biostatistics, Smoking Cessation, Hematology, Resp. Therapy/Physiotherapy, Patient/Survivors, Caregivers and Unknown.

MEMBERS BY GENDER

Male 55.6%
Female 37.7%
Unknown 6.6%
Non-binary/another gender .06%
Prefer to self-describe .04%

MEMBERS BY AGE

24 or below 1%
25-34 13%
35-44 29%
45-54 26%
55-64 20%
65-74 9%
75+ 2%

LOCATION-PROFESSIONAL ACTIVITY/PRACTICE

Academic Medical Center/University 48.3%
Other/Unknown 15.7%
Pharmaceutical/Biotech 10.7%
Cancer Center 10.4%
Private Practice (Hospital) 3.6%
Private Practice (Office) 3.1%
Training Program 2.6%
Non-Profit or Advocacy 1.9%
Laboratory Research 1.7%
Government Agency 1.1%
Administration 0.5%
Retired 0.4%

YEARS OF MEMBERSHIP

25+ 3%
16-24 7%
10-15 13%
6-10 19%
2-5 31%
1 or less 27%
SCIENTIFIC AFFAIRS

Every project that the IASLC dedicates itself to revolves around lung cancer research, across specialties and from around the globe. Whether that novel research is showcased in a new multi-day all-virtual symposium, a podcast or webinar with expert panelists who can put the data in context, or in an *IASLC Lung Cancer News* (ILCN) article that discusses the nuances of daily clinical application, we strive to support and promote practice-changing research, providing education to all of our volunteers and members.

**IASLC FLAGSHIP SCIENTIFIC PROJECTS | 2022**

**Staging: Improving Lung Cancer Staging through International Collaboration**

For more than 20 years, the IASLC Lung Cancer Staging Project has provided valuable recommendations for the TNM classification of lung cancer—jointly published by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC). The IASLC is currently analyzing data for the 9th edition of the TNM Staging System, which for the first time, will include new data elements such as gene mutations, fusions, number alterations, and protein expression levels. The goal of these additional tumor characteristics is to significantly enhance the accuracy of the Staging System, leading to more precise treatment regimens and increased patient survival.

Data collection for the 9th edition closed on December 31, 2021. In this edition, we collected the most data for any cycle of the TNM Staging Project, from more than 20 countries:

- **124,541** Lung Cancer cases
- **4,585** Mesothelioma cases
- **11,316** Thymic Malignancies cases

For the first time, the IASLC piloted a grant program for the Staging Project to provide funding for institutions located in low- to middle-income countries to submit data for the 9th edition. This funding allowed **16 institutions** from **12 countries** to contribute **9,739 total cases.** Learn more about the IASLC’s Staging Project.

New TNM Staging Classification will be available in late 2023.
IASLC Atlas on Molecular Biomarker Testing for Targeted Therapy In Lung Cancer

The IASLC has produced several atlases dealing with a range of lung cancer biomarker testing topics including ALK, ROS1, EGFR, and PD-L1 and also an atlas on immunohistochemistry for lung cancer diagnosis. These atlases provide state-of-the-art, concisely presented information on clinical, pathological, and molecular testing aspects of the subject material in a user-friendly package.

The IASLC is working on a comprehensive atlas covering all current and emerging targets from both a diagnostic and clinical point of view. There will be dedicated chapters for each ‘marker’ – EGFR, ALK, ROS1, MET, KRAS, RET, NTRK, NRG, and HER2 – each written by pathologists and medical oncologists, covering both the therapeutic and the testing aspects relevant to each family of genomic alterations. The atlas will also cover a few broadly focused chapters covering various aspects of precision medicine in lung cancer—like specimen acquisition and the handling of tumor samples, the different available assays, and interpretation of results to reporting and quality assurance. This atlas aims to serve as a comprehensive, concise, and hands-on educational resource for multidisciplinary medical professionals. **The Molecular Atlas is available now.**

**The Molecular Atlas:**
- Provides pathologists with “know-how” educational information on specimen acquisition (tissue and liquid), pre-analytical conditions, and molecular testing.
- Provides oncologists with the “know-why” educational information on how to interpret and potentially apply the results for a therapy where medically appropriate.
- Serves as an educational tool and hands-on resource for multidisciplinary medical professionals involved in precision medicine worldwide.

**Molecular Atlas Editors:**

Lynette M. Sholl, MD  
Ming-Sound Tsao, MD, FRCPC  
Wendy A. Cooper, BSc (Med), MBBS, PhD, FRCPA  
Keith M. Kerr, BSc, MBChB, FRCPATH, Hon FRCPED, Hon FRCSI  
James Chih-Hsin Yang, MD, PhD  
Daniel S.W. Tan, BSc (Hons), MBBS, MRCP

All IASLC Atlases & Resources can be found here.
Pathologic Response (PR) Initiatives

Before undertaking the Pathologic Response (PR) project by the IASLC and the LAA, there were no established guidelines for processing and evaluating resected lung cancer specimens, and there was a lack of precise definitions for the degree of pathological response following neoadjuvant therapy. These recommendations were published in the *Journal of Thoracic Oncology* in 2020.

The IASLC has nearly completed Phase 2 of the PR project, which aims to implement the IASLC recommendations by assessing a global cohort of pathologists’ reproducibility of histological Major Pathologic Response (MPR) and Complete Pathologic Response (cPR) assessments in surgical resection specimens of lung cancer patients treated with neoadjuvant immune checkpoint inhibitors with and without chemotherapy. Each of these steps will help the IASLC establish PR, MPR, and/or cPR, in surgical resection specimens following neoadjuvant therapies as predictors and surrogate markers of long-term clinical benefit in patients with resected stage I to III lung cancer. Learn more about the [PR project](#).

**Phase 2: IASLC Reproducibility Study**

The IASLC Reproducibility Study aims to determine reproducibility among pathologists of pathologic response determinations using the IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens following neoadjuvant therapy. This study brings together an international cohort of 11 pathologists to evaluate 60-90 NSCLC tumors treated with anti-PD-1 or PD-L1 alone or in combination with chemotherapy or anti-CTLA-4 therapy. This study is ongoing and is expected to conclude in early 2023.

**Phase 2B: Digital Quantification of Pathologic Response in Neoadjuvant Treated Non-Small Cell Lung Cancer (NSCLC)**

In this project, the IASLC will collaborate with PathAI to apply an AI-driven digital pathology assessment of pathologic response and compare this to manual assessments from the IASLC pathologic response interobserver study. This study will support the validation of an AI-powered assessment of pathological response. This project was conceptualized and fully funded in 2021 and is set to conclude in 2023.

**Phase 3: Lung Cancer Neoadjuvant Trial Endpoint Database (LCNTED)**

In the final phase of the IASLC Neoadjuvant Therapies in Lung Cancer Initiative, a multidisciplinary group will identify the data necessary, collect the required information from neoadjuvant trials worldwide, and execute the statistical analyses to support the use of pathologic response as a determinant of long-term outcomes. This process has been accomplished in the CTNeoBC-pooled analysis project analyzing neoadjuvant trials in breast cancers.

Following the lead of CTNeoBC in breast cancers, Phase 3 of the LCNTED initiative will:

1. Establish the association between pathologic response and event-free survival (EFS) and overall survival (OS);
2. Establish the definition of pathologic response, including MPR and CPR, that correlates best with long-term outcomes;
3. Identify the lung cancer subtypes in which pathologic response best correlates with long-term outcomes; and
4. Assess whether increases in pathologic response between treatment groups predict improved EFS and OS.

An initiative of this magnitude and importance requires the collaboration of multiple partners and stakeholders to make meaningful progress. Therefore, this initiative will bring together the IASLC membership, FDA regulators, and various leading industry partners, who all share the common goal of eliminating lung cancer as a cause of death. The IASLC will begin database design in 2023, data collection as early as 2024, with the project concluding in 2028.
Early Lung Imaging Confederation (ELIC)

The vision of the IASLC is to Conquer Thoracic Cancers Worldwide. One of the best ways to fulfill this vision, beyond risk reduction, is to detect cancers early. Effective low-dose computed tomography (LDCT) screening is critical to detecting and diagnosing lung cancer early and increasing survival. The Early Lung Imaging Confederation (ELIC) is an international alliance of collaborating individuals and institutions who share a vision to develop a globally distributed, privacy-secured, lung cancer imaging database and computational analysis environment. The fundamental goal of ELIC is to support the development of deep learning methods and artificial intelligence approaches to detect lung cancer and other diseases early using thoracic CT images, to characterize small pulmonary nodules and surrounding structures, and to measure responsiveness to therapeutic interventions. For more information about ELIC, please visit https://iaslc-elic.org/.

COLLABORATING RESEARCHERS

Stephen Lam, MD, FRCPC
British Columbia Cancer Research
Vancouver, Canada

Witold Rzyman, MD
Medical University of Gdansk
Gdansk, Poland

Kazuto Ashizawa, MD
Nagasaki University
Nagasaki, Japan

Ugo Pastorino, MD
IRCCS National Cancer Institute Foundation
Milan, Italy

Claudia Henschke, MD, PhD
Mount Sinai
New York, NY, United States

Annette McWilliams, MD
Fiona Stanley Hospital
Perth, Australia

Bruno Hochhegger, MD, PhD
Federal University of Health Sciences of Porto Alegre
Porto Alegre, Brazil
CancerLinQ

The IASLC, in partnership with Emory University, is working collaboratively with ASCO to expand the specialized expertise informing CancerLinQ®, a health information technology platform, developed by oncologists for oncologists, to enhance and improve the understanding and treatment of cancer. With leaders from Emory, we’ve investigated the database with three queries on: EGFR Exon 20 Insertion Mutations, molecular testing and patterns of treatment in NSCLC Patients, and Long-term Survival Outcomes in NSCLC Patients with targeted therapy and immunotherapy.

Additional Resources:

- **Natural History and Real-World Treatment Outcomes for NSCLC Patients with EGFR Exon 20 Insertion Mutation: An IASLC-ASCO CancerLinQ Study** (2021)
- **Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data** (2022)
- **Molecular Testing and Patterns of Treatment in Patients with NSCLC: An IASLC Analysis of ASCO CancerLinQ Discovery Data** (2022)
IASLC strives to provide quality education and networking opportunities to our members, and 2022 was no exception. We returned to in-person events with WCLC 2022 in Vienna followed by NACLC 2022 and ACLC 2022. Our members were excited to get to see and share information with each other face-to-face. However, we didn’t leave all of our new-found expertise in hosting virtual events behind, as each event also had a virtual option. Some sessions were live-streamed for those who could not be there in person, and videos of the events were also made available on demand.

As we move forward into 2023, we plan to continue providing both in-person and virtual options for our events, allowing everyone working to defeat thoracic cancers and malignancies access to the latest information and education in the field.

**IASLC 2022 CONFERENCES AND EVENTS**

**FEBRUARY 22-26, 2022 | WORLDWIDE VIRTUAL EVENT**

The IASLC 2022 Targeted Therapies of Lung Cancer Meeting took place February 22-26, 2022, as a worldwide virtual event. Meeting Chairs, *Drs. Paul A. Bunn, Jr.*, *Roy Herbst*, *Lecia Sequist*, *Suresh Ramalingam*, and *Charu Aggarwal* welcomed more than 1,050 participants from 47 countries to share information about ongoing clinical trials of the newest therapies for lung cancer.

Participants were encouraged to actively participate in discussions and engage with industry supporters. Presenters summarized the data on relevant targets for new therapies and shared data on preclinical and early clinical data for each of the drugs directed against these targets. For TTLC 2022, 53 abstracts were submitted and 19 exhibitors and sponsors participated in the meeting, with Genentech as the Diamond sponsor.
The World Conference on Lung Cancer (WCLC 22) returned to an in-person format in 2022. Chairs Drs. Robert Pirker, Eric Lim, Françoise Mornex, Silvia Novello, and Helmut Prosch welcomed 5,185 attendees from 103 countries. The event included a virtual component with all plenary sessions live-streamed and all sessions available online within 24 hours.

There was plenty for attendees to learn in the 5 plenary sessions, 39 education sessions, 15 oral sessions, 14 mini-oral sessions, 18 interactive breakfast sessions, and 8 workshops. In addition, 1,469 abstracts were submitted in 2022, with 1,119 accepted. For those interested in imaging advances, the CT Screening Symposium took place in person as a pre-conference event.

Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene-Driven NSCLC

The International Association for the Study of Lung Cancer, Chinese Society for Clinical Oncology, and the Chinese Alliance Against Lung Cancer presented outstanding educational and cutting-edge research during this on-demand session at the 2022 World Conference on Lung Cancer. Drs. Yi-Long Wu, Chunxue Bai, Caicun Zhou, and Karen Kelly presented research and global perspectives on Liquid Biopsy in Oncogene-Driven NSCLC, as well as three oral abstract presentations and a discussion of 10 posters based on research performed by our Chinese colleagues.

WCLC 2022 AWARD WINNERS

Each year, the IASLC honors professionals who have made major contributions to the field of thoracic cancers with its Distinguished Service Awards. The association distributes awards that recognize lifetime achievement in specific areas of practice, with the most significant honors—the IASLC Distinguished Service Awards—being distributed during the WCLC Opening Ceremony.
2022 LECTURESHIP AWARDS

During WCLC 2022, the IASLC presented Lectureship Awards to clinicians and researchers who made significant contributions to the fight against lung cancer. The awards represent major categories of lung cancer research, from tumor staging to tobacco control and smoking cessation. The 2022 IASLC Lectureship Awards winners include:

- **ROBERT J. GINSBERG LECTURESHIP AWARD FOR SURGERY**
  Isabelle Opitz, MD
  University Hospital Zurich
  Zurich, Switzerland
  Thoracic Surgery

- **CLIFTON F. MOUNTAIN LECTURESHIP AWARD FOR STAGING**
  Clarissa Mathias, MD, PhD
  NOB Oncoclinicas, Salvador
  Bahia, Brazil
  Oncology

- **IASLC LECTURESHIP AWARD FOR TOBACCO CONTROL AND SMOKING CESSION**
  Ray Osarogiagbon, MD
  Baptist Cancer Center
  Memphis, Tennessee
  Thoracic Oncology

- **JAMES D. COX LECTURESHIP AWARD FOR RADIATION ONCOLOGY**
  Yuko Nakayama, MD
  National Cancer Center
  Tokyo, Japan
  Radiation Oncology

- **FRED R. HIRSCH LECTURESHIP AWARD FOR TRANSLATIONAL RESEARCH**
  Lukas Bubendorf, MD
  University Hospital Basel
  Switzerland
  Surgical Pathology

- **TSUGUO NARUKE LECTURESHIP AWARD FOR SURGERY**
  Wenzhao Zhong, MD, PhD
  Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Science
  Guangzhou, Guangdong, China
  Surgery

- **DANIEL C. IHDE LECTURESHIP AWARD FOR MEDICAL ONCOLOGY**
  Patrick Forde, MD, MBCh
  Johns Hopkins Hospital
  Baltimore, Maryland
  Oncology

- **IASLC LECTURESHIP AWARD FOR NURSES AND ALLIED HEALTH PROFESSIONALS**
  Anne Fraser, NP
  Lung Foundation NZ
  Auckland, New Zealand

- **HEINE H. HANSON LECTURESHIP AWARD FOR SMALL CELL LUNG CANCER**
  Stephen Liu, MD
  Lombardi Comprehensive Cancer Center
  Georgetown University
  Washington, D.C.
  Thoracic Oncology

Learn more about the IASLC’s Distinguished Service Award Winners, Lectureship Award Winners, and Advocacy Winners.
### Quick Facts

<table>
<thead>
<tr>
<th>Category</th>
<th>Figures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Invited Speakers</td>
<td>324</td>
</tr>
<tr>
<td>Number of Plenary Speakers</td>
<td>26</td>
</tr>
<tr>
<td>Invited Session Chairs</td>
<td>199</td>
</tr>
<tr>
<td>Featured &amp; E-Posters</td>
<td>970</td>
</tr>
<tr>
<td>Discussants</td>
<td>51</td>
</tr>
</tbody>
</table>

### Education Awards

<table>
<thead>
<tr>
<th>Award Type</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Career</td>
<td>10x</td>
</tr>
<tr>
<td>Developing Nations</td>
<td>9x</td>
</tr>
<tr>
<td>Nurse/Allied Health Professional</td>
<td>4x</td>
</tr>
<tr>
<td>Patient Advocate Education</td>
<td>3x</td>
</tr>
</tbody>
</table>

### Other Figures

<table>
<thead>
<tr>
<th>Category</th>
<th>Figures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegates</td>
<td>5,185</td>
</tr>
<tr>
<td>Countries</td>
<td>103</td>
</tr>
<tr>
<td>CME Credits Offered</td>
<td>66.5</td>
</tr>
<tr>
<td>Live Q&amp;A Panel Discussions</td>
<td>47</td>
</tr>
<tr>
<td>Exhibitors</td>
<td>38</td>
</tr>
<tr>
<td>Symposium</td>
<td>18</td>
</tr>
<tr>
<td>Raised for International Lung Cancer Foundation*</td>
<td>$100,000</td>
</tr>
</tbody>
</table>

*(includes Benefit Event & STEPS Challenge)*

### Global Media Coverage

<table>
<thead>
<tr>
<th>Category</th>
<th>Figures</th>
</tr>
</thead>
<tbody>
<tr>
<td>News Releases Issued</td>
<td>42</td>
</tr>
<tr>
<td>Scientific Releases</td>
<td>38</td>
</tr>
<tr>
<td>Awards Releases</td>
<td>8</td>
</tr>
<tr>
<td>Registered Journalists</td>
<td>120</td>
</tr>
<tr>
<td>Total Media Mentions</td>
<td>65,600</td>
</tr>
<tr>
<td>Views of IASLC News Releases on Eurekalert by Journalists</td>
<td>17,585</td>
</tr>
<tr>
<td>Total Number of Countries in which Meeting was Covered</td>
<td>131</td>
</tr>
<tr>
<td>Press Briefings</td>
<td>4</td>
</tr>
</tbody>
</table>

*Education & Conferences*
IASLC 2022 CONFERENCES AND EVENTS

IASLC 2022 CT SCREENING SYMPOSIUM:
FOREFRONT ADVANCES IN LUNG CANCER SCREENING
AUGUST 6, 2022 | VIENNA, AUSTRIA

The CT Screening Symposium was a one-day, immersive, in-person event featured at WCLC 2022 focused on lung cancer screening technologies and best practices. Using a mix of live educational presentations, real-time expert discussions, and interactive live Q&A opportunities, the Symposium addressed topics relevant to our international audience. Faculty provided anecdotal experience and reviewed current data highlighting successes and addressing barriers to implementing more uniform and effective lung cancer screening worldwide.

IASLC 2022 CONFERENCES AND EVENTS

NACLC 2022 offered myriad opportunities for networking and education for attendees. The meeting focused on the most up-to-date research, diverse topics of interest, and educational sessions with leading experts. Chairs Drs. Jessica Donington, Marina Garassino, and Jyoti Patel created an event that met the needs of both our in-person attendees and our virtual ones.

The event hosted 568 attendees from 25 countries. We had 65 chairs and speakers and 19 sponsors and exhibitors. Attendees learned from 6 symposia, 89 posters, and 108 abstracts.

ACLC 2022 returned this year with an in-person meeting in Nara, Japan. The conference highlighted the latest research in the field of thoracic cancer and malignancies while providing plenty of opportunity for face-to-face networking. Chaired by Drs. Tetsuya Mitsudomi, Myung-Ju Ahn, and James CH Yang, the event brought together experts working in a variety of disciplines to facilitate a shared knowledge base across the specialty.

The conference hosted 511 attendees representing 37 countries. Attendees heard from 111 speakers and interacted with 9 sponsors and exhibitors. Research and information was shared through 7 symposia, 118 posters, and 167 abstracts. ACLC 2022 was the first international meeting to take place at the Nara Convention Center since the pandemic began.

Looking ahead to 2023, the IASLC is committed to maintaining our high-quality education to ensure our members have the necessary resources to eradicate lung cancer and other thoracic malignancies worldwide. IASLC continues to monitor the COVID-19 pandemic and public safety and will continue to offer in-person and digital meeting options for most of our 2023 IASLC programs. It is a primary goal that the IASLC continues to be the leader in lung cancer and thoracic oncology education, by providing practice-impacting education and networking opportunities to advance groundbreaking research to its membership.
WEBINARS

Webinars are an important part of IASLC’s offerings, providing education and insight to those in the thoracic cancer community. In 2022, 686 people attended IASLC webinars, representing multiple specialties, geographical regions, and both IASLC members and non-members.

2022 IASLC Webinars

January - Updates on Liquid Biopsy for Advanced NSCLC: A Consensus Statement from the IASLC

There have been major advancements in therapies and diagnostics for advanced-stage non-small cell lung cancer over the past few years and these have led to meaningful increases in survival. One of the biggest advances is in therapeutics and diagnostics for molecular alterations that drive the oncogenic process. Tumor tissue has been the accepted standard biospecimen but there can be limitations with tissue, including collection and analysis. Thus, liquid biopsy, primarily blood plasma, represents a practical alternative source for determining tumor-derived somatic alterations.

Faculty: Dr. Christian Rolfo, Dr. David Gandara and Dr. Natasha B. Leigh

April - Emerging Perioperative Treatment Using Immune Checkpoint Inhibitors in Patients with Resectable NSCLC

Immune checkpoint inhibitors and EGFR-TKIs, which have shown efficacy in advanced lung cancer, are now being applied to perioperative treatment. Many agents are expected to be introduced into the perioperative treatment of resectable Stage IB to Stage III, but the balance of efficacy and adverse events varies for each subset of patients. In using each agent in clinical practice, the debate continues as to whether a new perioperative therapy should be recommended for all patients or for a subset of patients. In this webinar, we strove to deepen the discussion on immune checkpoint inhibitors in the perioperative setting.

This was a joint webinar between IASLC and JLCS (Japan Lung Cancer Society, https://www.haigan.gr.jp/).

Moderators: Dr. Hidehito Horinouchi & Dr. Tetsuya Mitsudomi
Speaker: Dr. Enriqueta Felip
Panelists: Dr. Tasushi Yatabe, Dr. Hirotsugu Kenmotsu and Dr. Yasuhiro Tsutani

August - American Society of Clinical Oncology (ASCO 2022) Meeting Highlights

This one-hour live session synthesized lung cancer research presented at the June 3-7 live meeting of the American Society of Clinical Oncology (ASCO). It addressed physicians’ need to keep abreast of current research and future trends to inform clinical practice.

Moderator: Dr. Antoinette Wozniak
Presenters: Dr. Shirish M. Gadgeel and Dr. Karen Reckamp

October - IASLC-STARS Webinar: Real-World Data (RWD) Leading to Real-World Evidence (RWE)

This one-hour session highlighted real-world data leading to real-world evidence. The webinar was hosted by the Research Advocacy Network (RAN) and was presented in English. The webinar was also translated into Spanish, German, Dutch, and French.

Moderator: Janet Freeman-Daily
Presenters: Dr. Bellinda King-Kallimanis and Dr. Upal Basu-Roy

November - ESMO 2022 NSCLC Highlights

This one-hour live session synthesized lung cancer research presented at the September 9-13 meeting of the European Society for Medical Oncology (ESMO). It addressed physicians’ need to keep abreast of current research and future trends to inform clinical practice.

Moderator: Dr. Nicolas Girard
Presenters: Dr. Lizza Hendriks and Dr. Jordi Remon
2022 TOTAL WEBINAR DATA

ATTENDEES BY PRIMARY SPECIALTY

- Medical Oncology: 21.8%
- Thoracic Surgery: 17.9%
- Pulmonary Medicine: 13.4%
- Biotech/Pharmaceutical Industry: 13.0%
- Other: 9.9%
- Cancer Research/Basic Sciences: 6.9%
- Pathology: 5.4%
- Advocacy: 4.5%
- Radiation Oncology: 2.5%
- Pharmacy: 1.7%
- Nursing: 1.4%
- Biostatistics: 0.6%
- Diagnostic Radiology: 0.8%
- Resp Therapy/Physiotherapy: 0.2%

ATTENDEES BY CONTINENT

- ASIA: 46.21%
- NORTH AMERICA: 34.55%
- EUROPE: 16.03%
- SOUTH AMERICA: 1.47%
- AFRICA: 0.87%
- AUSTRALIA: 0.87%

686 TOTAL ATTENDANCE

- Physicians*: 38%
- Non-physicians*: 62%
- Members: 35%

*Based on 2 webinars

CLICK TO ACCESS RECORDED WEBINARS
JTO & JTO CRR

PROVIDING IMPACTFUL AND ACCESSIBLE RESEARCH FOR THE LUNG CANCER COMMUNITY

JOURNAL OF THORACIC ONCOLOGY

The Journal of Thoracic Oncology (JTO), the IASLC’s official journal, is the authoritative publication for education and information related to all aspects of thoracic malignancies. The JTO includes original research, reviews, and opinion pieces, and reaches a diverse audience, including epidemiologists, statisticians, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.

It is generally difficult for organ-specific oncology journals to make a significant impact in the oncology publishing landscape. With an Impact Factor of 20.121, JTO is the leading journal in thoracic oncology and in the top fifteen (ranked 13th) of all cancer journals. JTO’s emphasis on multidisciplinary research is one of its strengths and serves the broad community of researchers in this field.

- Alex A. Adjei, MD, PhD
Editor-in-Chief

JTO Impact Factor* increases to 20.121!

JTO MOST CITED ARTICLES PUBLISHED IN 2022

<table>
<thead>
<tr>
<th>Citations (2022)</th>
<th>Article Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>IMPower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain</td>
<td>Nogami N., Barlesi F., Socinski M.A., Reck M., Thomas C.A., et al.</td>
</tr>
<tr>
<td>27</td>
<td>Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses</td>
<td>Gounant V., Ferre VM., Soussi G., Charpentier C., Flamant H., et al.</td>
</tr>
</tbody>
</table>

(Source: Elsevier)
JTO & JTO CRR
PROVIDING IMPACTFUL AND ACCESSIBLE RESEARCH
FOR THE LUNG CANCER COMMUNITY

JTO CLINICAL AND RESEARCH REPORTS

JTO Clinical and Research Reports (JTO CRR) transitioned to article-based publishing and became a monthly publication in 2021. In just 10 short months, JTO CRR was indexed in PubMed Central. The journal is now in the process of application to be evaluated and to enter the Emerging Source Citation Index (ESCI), part of the Web of Science core collections. (The journal will receive an impact factor a year after being indexed in ESCI).

Dr. Emily Stone, MBBS, PhD, FRACP officially took the reins as the Editor-in-Chief of JTO CRR on January 9, 2023, as Dr. Alex Adjei steps down from the role. Dr. Stone is a consultant respiratory physician and Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St. Vincent’s Hospital Sydney. The editorial teams are excited for the next chapter under Dr. Stone’s editorial leadership and strategic stewardship of JTO CRR.

JTO CRR’s success and continued growth are a reflection of the support of our readers, authors, and reviewers. This open-access journal broadens the reach of the IASLC throughout the world, offering unfettered access to the thoracic oncology community.

JTO CRR MOST CITED ARTICLES, 2022

<table>
<thead>
<tr>
<th>Citations (Lifetime)</th>
<th>Article Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>Catalog of 5' fusion partners in RET+ NSCLC Circa 2020</td>
<td>Ou S.-H.I., Zhu V.W.</td>
</tr>
<tr>
<td>15</td>
<td>A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020</td>
<td>Ou S.-H.I., Nagasaka M.</td>
</tr>
<tr>
<td>3</td>
<td>Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorsib: Case Report</td>
<td>Begum P., Goldin R.D., Possamai L.A., Popat S.</td>
</tr>
</tbody>
</table>

(Source: Scopus)
The IASLC Lung Cancer News (ILCN) is the IASLC’s official news source for thoracic oncology specialists around the globe. ILCN provides its international audience with timely and relevant lung cancer news on topics across specialties and interests, including medical, radiation, and surgical oncology, as well as patient advocacy, nursing and allied health, and pathology. Led by Editor Dr. Corey Langer, ILCN is filled with nuanced expert perspectives on topics that span the lung cancer care continuum, from screening through survivorship to end-of-life conversations.

With new content posted to ilcn.org every two weeks, readers will regularly find content applicable to their specialty and interests. A twice-monthly digital edition is delivered directly to the inboxes of all IASLC members.

For more information about ILCN’s editorial group, visit: https://www.iaslc.org/iaslc-news/ilcn-editorial-group

THE VOLUNTEERS WHO MAKE ILCN POSSIBLE

EDITOR
Corey J. Langer, MD, FACP
USA

ASSOCIATE EDITOR
Fabrice Barlesi, MD, PhD
France

ASSOCIATE EDITOR
Caicun Zhou, MD, PhD
China

D. Ross Camidge, MD
Edgardo S. Santos Castillero, MD, FACP
José Francisco Corona Cruz, MD
Anne-Marie C. Dingemans, MD, PhD
Ivy Elkins Patient Advocate
Mary Jo Fidler, MD
Shirish Gadgeel, MD

Bruno Hochhegger, MD, PhD
Angus Pratt, MBA Patient Advocate
Karen Reckamp, MD
Christian Roito, MD, PhD, MBA
Witold K. Rzyman, MD
Ricardo Sales dos Santos, MD, PhD
Joan Schiller, MD

Suresh Senan, MD
Brendon Stiles, MD
Aaron Tan, MD
Ricardo Terra, MD, PhD, MPH
Murry Wynes, PhD
Erin Jungmeyer Managing Editor
Jan Mazotti Staff Liaison
BY THE NUMBERS

In 2022, ILCN received 154,240 unique page views by 86,180 users that cover the globe. The top 10 countries represented by ILCN’s 80,000+ readers are:

USA  CHINA  UK  INDIA
CANADA  JAPAN  ITALY  TAIWAN
NETHERLANDS  GERMANY

THE TOP 10 MOST-READ ILCN ARTICLES OF 2022

1. Comments on 8th Edition of TNM Classification of Lung Cancer (Read 5,362 times)
2. A Holistic Approach to Patient Care (Read 5,187 times)
3. Lung Cancer in Never-Smokers: An Epidemiologic Perspective (Read 4,165 times)
4. Valuable Intersections: Maximizing Career Opportunities Arising From the Relationship Between Academia and Industry (Read 3,115 times)
5. Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates (Read 2,531 times)
6. Controversy Regarding U.S. Marketing of New Heated Tobacco Product IQOS (Read 2,386 times)
7. Alternative Dosing Strategies for Immune Checkpoint Inhibitors (Read 2,355 times)
8. A New Standard of Care in EGFR-Positive NSCLC Unresponsive to TKIs? (Read 1,759 times)
9. Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients (Read 1,641 times)
10. CT Findings of COVID-19 Pneumonia and Mimicking Diseases in Patients with Lung Cancer (Read 1,372 times)
Tune in to Lung Cancer Considered, the official IASLC podcast, for conversations with the researchers, healthcare professionals, patients, and advocates who make a difference in treating thoracic cancers.

During 2022, listenership of the podcast surpassed 100,000 listeners, and the podcast won the w3 Gold Award for creative excellence.

Lung Cancer Considered also began streaming on Apple Podcasts and Spotify, as well as SoundCloud during 2022.

Listen here and join the conversation.
2022 TOTAL PODCAST DATA

LISTENS BY YEAR

<table>
<thead>
<tr>
<th>Year</th>
<th>Listens</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>6,087</td>
</tr>
<tr>
<td>2020</td>
<td>13,557</td>
</tr>
<tr>
<td>2021</td>
<td>44,356</td>
</tr>
<tr>
<td>2022</td>
<td>49,707</td>
</tr>
</tbody>
</table>

130,615 ALL-TIME LISTENS

TOP COUNTRIES

- UNITED STATES - 79,955
- AUSTRALIA - 8,236
- JAPAN - 6,580

MOST USED WEBSITES, RSS AND THIRD-PARTY APPS

- www.iaslc.org 6,018
- AppleCoreMedia iPhone 11,381
- RSS Feed 113,118

TOP 10 PODCASTS IN 2022

<table>
<thead>
<tr>
<th>Title of Podcast</th>
<th>Total Listens</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCO 2022 Highlights</td>
<td>1,717</td>
</tr>
<tr>
<td>WCLC 2022 Daily Highlights</td>
<td>1,687</td>
</tr>
<tr>
<td>Overview of EGFR in NSCLC</td>
<td>1,547</td>
</tr>
<tr>
<td>Targeting ALK in NSCLC</td>
<td>1,520</td>
</tr>
<tr>
<td>Virtual Tumor Board: EGFR Mutant NSCLC</td>
<td>1,377</td>
</tr>
<tr>
<td>TTLC 2022 Highlights</td>
<td>1,365</td>
</tr>
<tr>
<td>Antibody Drug Conjugates (ADCs) in NSCLC</td>
<td>1,330</td>
</tr>
<tr>
<td>Climate Change &amp; Lung Cancer: Part One</td>
<td>1,294</td>
</tr>
<tr>
<td>Targeting NTRK in NSCLC</td>
<td>1,278</td>
</tr>
<tr>
<td>Virtual Tumor Board: Advanced PD-L1 negative NSCLC</td>
<td>1,272</td>
</tr>
</tbody>
</table>
Volunteers are the heart of IASLC committees as each member contributes their specialized skills and talents to help define the work of the organization, develop educational content, shape the association’s messaging, plan annual meetings, contribute to IASLC publications, and more.

Each committee reports to the IASLC Board of Directors and has a chair (or co-chairs), a board liaison, and a staff liaison. Committee members are currently in the middle of their 2021-2023 term, and each committee was carefully selected to ensure relevant expertise, as well as diversity by region and gender.

Advanced Radiation Technology (ART) Committee

Members of the ART committee have planned multiple educational webinars and podcasts, published extensively in the JTO, and collaborated with other radiation oncology societies to develop new guidelines and content this year, including “Avoiding Toxicity with Lung Radiation Therapy: An IASLC Perspective” in May 2022. Dr. Fiona McDonald of The Royal Marsden Hospital in the United Kingdom is the Committee Chair.

Career Development & Fellowship Committee

The Career Development and Fellowship Committee focuses on providing support for the next generation of lung specialists by awarding research grants. The committee reviews and scores grant applications and selects grant recipients. Dr. Ahmed Rabea of the National Cancer Institute of Egypt is the committee chair. In 2022, the Committee reviewed 91 applications and selected 14 recipients, awarding grants totaling $850,000.

Communications Committee

The Communications Committee develops campaigns to increase IASLC brand recognition and credibility while educating the public about complex lung and thoracic cancer issues. In addition, the committee chooses articles from the Journal of Thoracic Oncology to promote to the media to enhance public understanding of lung and thoracic cancer. Through press releases, Lung Cancer Considered podcasts, and ILCN articles, Communications Committee members work to enhance the visibility of IASLC on an international stage and provide IASLC members, the thoracic oncology community at large, and the media with accurate and timely perspectives on hot topics in lung cancer. At WCLC 2022, members of the Communications Committee offered a social media and communications workshop, where attendees learned from lung cancer influencers how to work with communications teams, build a personal brand, promote research and advocacy through traditional and social networks, give the perfect interview, and engage in the Latin American and Asian markets. Dr. Brendon Stiles of the Montefiore-Einstein Cancer Center in New York is the committee chair.
**Continuing Medical Education Committee**

In 2022, the IASLC was granted another four years as an ACCME CME Provider. The CME Committee ensures that all accredited activities meet the ACCME Accreditation Requirements, including the ACCME Standards for Integrity and Independence in Accredited Continuing Education™. The CME Committee also makes sure that IASLC CME activities meet the requirements of the American Medical Association Physician’s Recognition Award (AMA PRA). Dr. Apar Kishor Ganti of the University of Nebraska Medical Center and Dr. Nick Pavlakis of the Royal North Shore Hospital in Australia co-chair the committee.

**Education Committee**

The Education Committee lives out IASLC’s mission to provide education and information about lung cancer and other thoracic malignancies to IASLC members, the medical community at large, and the public. The committee works to identify educational needs and practice gaps, develop learning objectives, design accredited and non-accredited educational programs, and evaluate the effectiveness of IASLC educational activities. The Education Committee and the Continuing Medical Education committee work together to ensure activities meet the IASLC CME Mission and are implemented in compliance with ACCME. Dr. Christian Rolfo of the Tisch Cancer Institute at Mount Sinai in New York is the committee chair.

**Membership Committee**

In 2022, as part of its responsibilities, the Membership Committee assisted IASLC staff with the 2022 Member Survey, which provided valuable insight into our members and their needs. The committee members also helped to plan the Committee Corner at WCLC 2022 along with their regular duties of reviewing and recommending membership status requirements and benefits for all IASLC members. The committee sets strategy and implements tactics to increase and retain association membership across specialties and regions. The committee focuses on sharing the message of the IASLC and ensures the benefits it offers are a great value for thoracic oncology professionals and fosters relationships with new members from around the globe. Dr. Nan Wu of Peking University Cancer Hospital & Institute in China is the committee chair.

**Mesothelioma Committee**

The Mesothelioma Committee seeks to accelerate the pace of research and work across geographies to develop strategic research goals and to bring the disease to the forefront of research. In 2022, the committee organized a joint workshop at WCLC 2022 to share the outlook on the future of mesothelioma treatment, including new drugs, pathological and biological breakthroughs, and educational panel discussions with leaders in the field. Several research updates in mesothelioma in recent years have been spearheaded by members of the Mesothelioma Committee. The committee is chaired by Dr. Paul Baas of The Netherlands Cancer Institute.
**Nursing & Allied Health Professionals Committee**

The Nursing & Allied Health Professionals Committee (NAHP), composed of multidisciplinary clinicians and researchers each with a unique perspective, is committed to advancing the education of both practitioners and patients in thoracic oncology. The committee’s goal is to improve and optimize outcomes for oncology patients and families across the cancer trajectory through diagnosis, treatment, survivorship, and end-of-life. In 2022, the NAHP Committee collaborated with ITONF at WCLC 2022 to host a workshop featuring global leaders discussing targeted therapies in NSCLC; addressing symptom management, palliative care, & survivorship; unlocking the secrets of immunotherapy; addressing stigma & shame; working across borders, and more. Dr. Maria Ftnou of Peter MacCallum Cancer Center in Australia is the committee chair.

---

**Pathology Committee**

The Pathology Committee helps fulfill core aspects of IASLC’s mission, including producing publications, such as the IHC Atlas, offering guidance for the organization’s annual slate of meetings, and helping to establish the IASLC as an international leader in the clinical and scientific aspects of lung cancer pathology. During 2022, the Committee authored and published three pioneering JTO articles including:

- **Defining morphologic features of invasion in pulmonary non-mucinous adenocarcinoma with lepidic growth – A proposal by the IASLC Pathology Committee**
- **Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee**
- **NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma**

This team is also instrumental in the IASLC’s Pathologic Response Initiatives and the research and publication of the Molecular Atlas. Dr. Wendy Cooper of the Royal Prince Alfred Hospital in Australia chairs the Pathology Committee.

---

**Patient Advocates Committee**

The Patient Advocates Committee addresses the direct impact research has on its beneficiaries—patients with lung cancer—and how they can support continued research to improve treatment options and availability. In 2022, the committee launched the Patient Advocacy Survey to determine how IASLC has been meeting patient advocate needs and how we can make improvements in the future. The survey was sent to IASLC members who identify as patient advocates and was also made available to the general public. Once analyzed, the survey results will help make sure IASLC offerings for patient, survivor, and caregiver/partner members are effective and reach their intended users. The committee also explored collaboration opportunities to create patient guides and resources, including patient-friendly research summaries. Members also revamped the Education Awards and Cancer Care Team Award and collaborated with other IASLC committees, providing input and a patient advocacy perspective to other focus areas. Jill Feldman of EGFR Resisters chairs the Patient Advocates Committee.
Screening and Early Detection Committee

The IASLC Screening and Early Detection Committee is a multi-disciplinary group dedicated to advancing screening and early detection programs through education and research across the globe. Committee members include leaders from radiology, thoracic surgery, pulmonary medicine, medical oncology, nursing, basic science, and advocacy organizations from North America, Europe, Asia, and South America. Dr. Stephen Lam of the BC Cancer Center in Canada is the chair of the Screening and Early Detection Committee. The Committee is focused on climate change, specifically air pollution and lung cancer, and published the Air Pollution and Lung Cancer – The IASLC Position Statement and encouraged global policy makers to include LDCT screening for lung cancer in national screening recommendations in the EU Call for Evidence: Cancer Screening Recommendation Update and will be publishing a white paper in 2023 focused on LDCT.

Staging & Prognostic Factors Committee

The Staging & Prognostic Factors Committee works to study and improve the current staging system for lung cancer, as well as for thymic, esophageal cancers, and mesothelioma. Staging lung cancer and other thoracic malignancies accurately is critical in deciding treatment regimens and ensuring the best standardized care for patients worldwide. For the past 20 years, the committee has been instrumental in producing evidence-based recommendations for the TNM Classification for Thoracic Cancers, published by the Union for International Cancer Control (UICC) and the American Joint Council on Cancer (AJCC). Committee members are currently working to develop recommendations for the ninth edition of TNM. Dr. Hisao Asamura of Keio University School of Medicine in Japan chairs the committee.

Tobacco Control and Smoking Cessation Committee

The Tobacco Control and Smoking Cessation Committee seeks to provide advice and direction to activities and initiatives that the association should engage in to reduce the use of tobacco worldwide. The committee ensures that IASLC addresses the needs of practitioners seeking to help their patients stop tobacco use and recommends actions to contribute to international and local/national, efforts in tobacco control initiatives and interventions. In 2022, the Tobacco Control and Cessation Committee updated the IASLC Position Statement on Tobacco Cessation After a Cancer Diagnosis, signed onto multiple tobacco-related initiatives, and worked with the IASLC Board of Directors to create two awards at WCLC 2023 to incentivize submissions on tobacco control and smoking cessation. The committee is chaired by Dr. Bill Evans of McMaster University in Canada.
PATIENT ADVOCACY

Advances in the early detection of lung cancer, care of patients living with lung cancer, and novel treatment options have experienced phenomenal growth over the past decade. The IASLC recognizes the importance and value that patients with lung cancer, their caregivers, and patient advocates bring to the lung cancer community and to the organization. We value inclusivity, and we hope to increase the pace of knowledge sharing and advancements in care by offering the patient advocate audience opportunities to:

• Attend conferences;
• Form relationships with researchers and care providers;
• Lend their voices, sitting side-by-side with researchers and members of the care team; and
• Share their perspectives and experiences.

IASLC Supportive Training for Advocates on Research & Science (STARS)

The IASLC STARS program aims to increase the number of patient research advocates (PRAs) equipped to provide accurate scientific translation in their online or real-life groups for patients with lung cancer and their caregivers and to provide the patient perspective for lung cancer research and policy.

Research advocates (PRAs) are volunteers with a personal connection to lung cancer who are passionate about helping research translate into meaningful outcomes for patients and their families. The 2022 STARS program focused on supporting STARS alumni by providing education in their areas of interest in research advocacy. PRAs participated in the program virtually throughout the year, with in-person networking opportunities at WCLC 2022, including an expert-led poster walk.

PATIENT RESEARCH ADVOCATES

Laura Book
USA

Lisa Briggs
USA

Sarah Christ
USA

Diane Colton
CANADA

Terri Conneran
USA

Seamus Cotter
IRELAND

Caleb Egwuenu
NIGERIA

Shelly Engfer-Triebenbach
USA

Tiffany Fagnani
USA

Laura Greco
USA

Tomma Hargraves
USA

Lily Huang
NEW ZEALAND

Leslie LaChance
USA

Kimberly Lester
USA

Nabanita Mandal
INDIA
PATIENT RESEARCH ADVOCATES

Susan McCullough
AUSTRALIA

Anita McGrath
AUSTRALIA

Jacquelyn Nixon
USA

Stella O’Brien
UNITED KINGDOM

Korina Pateli-Bell
GREECE

Angus Pratt
CANADA

Andrea Redway
CANADA

Mike Smith
USA

Baerbel Soehlke
GERMANY

Debra Violette
USA

Tom Wood
AUSTRALIA

Christine Q Wu
CANADA

Wayne Yeung
USA

STARS was developed by the IASLC in collaboration with lung cancer research advocates and patient advocacy nonprofits. In 2022, we appreciate our continued partnership with the Research Advocacy Network.

THANK YOU TO OUR 2022 SPONSORS
IASLC CANCER CARE TEAM AWARD

The IASLC Cancer Care Team Award is a prestigious award honoring and recognizing outstanding patient care served by multidisciplinary teams working together. Nominations are accepted from all over the world by individual patients with lung cancer and/or their caregivers/care partners. The IASLC is proud to honor the following winning teams of the 2022 IASLC Cancer Care Team Award:

North America Regional Winner — Baptist Cancer Center, Memphis, TN

Dr. Raymond Osarogiagbon, Medical Oncologist, Lead Nominee

“The entire team was always compassionate, professional, and offered me hope for a cure. Dr. Osarogiagbon was very understanding, gave me the facts, and hope for the future. He said that they will always take care of me. I never felt rushed. I did have good and bad days. But the team got me through it.”

– Marge Smith, patient and nominator for the North America team

Latin America Regional Winner — Instituto Nacional del Tórax, Providencia, Chile

Dra. María Paz Saavedra, Pneumonologist Lung Cancer Department, Lead Nominee

“My mother’s medical oncologist and the entire team explained (the situation to) us (without) any doubt. This happened all the time with an excellent disposition. These included: sharing with me support group information, and very helpful information on workshops with psychologists and oncologists, and also, activities with the palliative care team.”

– Loreto Aguinaga Cordova, a family member and caregiver who nominated the Latin American team

Asia/ROW Regional Winner — Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai, China

Dr. Caicun Zhou, Medical Oncologist, Lead Nominee

“They are a very professional team with rich experience and enough patience to get to know patients one-on-one and tell them how to face cancer. Unlike some doctors, they are very concerned about the mental health of their patients and often tell their patients that a good attitude is the first step in overcoming the disease. Rather than forcing the patient to do what they do, they give the patient choices that are often the best for the patient.”

– Weiran (Cici) Cao, caregiver and nominator of the Asia/ROW team

CANCER CARE TEAMS FROM NORTH AMERICA, LATIN AMERICA, AND ASIA ARE RECOGNIZED FOR THEIR EXEMPLARY CARE.
With the addition of new staff, IASLC implemented a relationship-driven corporate fundraising program. This included monthly calls with partners and in-depth meetings at multiple conferences. The team surpassed fundraising goals by strengthening partnerships, expanding the sponsorship portfolio, and developing innovative opportunities to create value both for the IASLC and its partners.

In addition to our meeting and event opportunities, we also offered specialized partnerships to support the development of IASLC resources, programs, scientific projects, and more.

We would like to extend a sincere thank you to the top sponsors of 2022.

To explore all the opportunities to engage with the IASLC, please contact us at corporaterelations@iaslc.org.
Despite advances in research and early detection that are creating better outcomes and hope for lung cancer patients and their families, lung cancer claims more lives each year than breast, colon, and prostate cancers combined. Yet lung cancer receives disproportionately less government research funding per cancer death than other types of cancer. This makes the need for private support of lung cancer research, like that provided to the IASLC Foundation, LLC, critical.

Donations from patients, caregivers, other individuals, as well as from our organizational and corporate partners, directly fund our Research Grants Program—a global education initiative funding fellows and young investigators undertaking innovative research to eradicate lung cancer and other thoracic malignancies.

**Gifts from the Estate of Dr. Adi Gazdar**

The Foundation is profoundly grateful to have been named as a beneficiary of the estate of Dr. Adi Gazdar. Dr. Adi Gazdar’s wife, Celia, passed away on March 23, 2022, causing the execution of the estate. In 2022, the Foundation received just over $1.15 million from the Gazdars’ estate.

A longtime member and former Board Member of the IASLC, Dr. Gazdar bequeathed to the IASLC/ILCF all license fees and royalties for the biological reagents (cell lines) that he generated while employed by the University of Texas Southwest Medical Center and the National Institutes of Health. This bequest will generate approximately $65,000 in ongoing annual revenue for the Foundation. Dr. Gazdar also bequeathed a lump sum of $500,000 as well as “all the rest and residue” of his estate. Dr. Gazdar’s will stipulates that the funds be used “for fellowships in lung cancer research in my name.” In honor of Dr. Gazdar and his exceptional gift, the Foundation’s Fellowship Grant will hereafter be named the “Adi F. Gazdar Fellowship Grant.”

**2022 Individual Donations**

The ILCF had another successful fundraising year in 2022, receiving $78,426 in individual donations. We thank each individual who donated to support lung cancer research in 2022. Please [click here](#) for the full list of our 2022 donors.

**2022 Research Grants Program**

In 2022, the Foundation awarded 14 Research Grants totaling $850,000. This year’s grant recipients represent another diverse group of early-career researchers from around the world. The ILCF Research Grants are made possible by donations from individual donors, foundation partners, and pharmaceutical companies and foundations.
2022 YOUNG INVESTIGATOR GRANT RECIPIENTS

Dr. Lawson Eng, Princess Margaret Cancer Centre, Canada
Project Title: Understanding the Impact of Age and Frailty on Immune Checkpoint Inhibitor (ICI) Outcomes in Lung Cancer Patients

Dr. Molly Siu Ching Li, The Chinese University of Hong Kong, Hong Kong
Project Title: Elucidation of Intratumoral Heterogeneity of ALK-rearranged Non-Small Cell Lung Cancer and its Clinical Impact

Dr. Colin Lindsay, The Christie NHS Foundation Trust, United Kingdom
Project Title: Functional Examination of NF1 Co-Mutation in KRAS Codon 13 Mutated Non-Small Cell Lung Cancer

Dr. Zsolt Megyesfalvi, National Koranyi Institute of Pulmonology, Hungary
Project Title: Identification of Subtype-Specific Small Cell Lung Cancer Biomarkers with Multiomic Approaches

Dr. Stephanie Saw, National Cancer Centre Singapore, Singapore
Project Title: PROgnostic Value of PD-L1 Score Post-Surgery in EGFR-Mutated Lung Cancer (PROSPER)

Dr. Gavitt Woodard, Yale University School of Medicine, United States
Project Title: Gene Expression and T-cell Dysfunction in Enlarging Semi-Solid Lung Adenocarcinomas

2022 FELLOWSHIP GRANT RECIPIENTS

Dr. Adithya Balasubramanian, Walter & Eliza Hall of Medical Research (WEHI), University of Melbourne, Australia
Project Title: Targeting Immune Resistance Mechanisms to Enhance Anti-Tumour Immunity in Non-Small Cell Lung Cancer

Dr. Diego Serrano, Universidad de Navarra, Spain
Project Title: Development of Novel Strategies to Fight Locoregional Recurrence in Lung Cancer Based on the Discovery of Radiosensitizing Therapies

Dr. Ting-Yu Shih, Boston University, United States
Project Title: Treating Lung Adenocarcinoma with a Tumor-Targeting Therapy

Dr. Lavanya Sivapalan, Sidney Kimmel Cancer Center, Johns Hopkins University, United States
Project Title: Evolutionary Trajectories of Tumor and the Tumor Microenvironment for Early-Stage Non-Small Cell Lung Cancer in the Context of Neoadjuvant Immunotherapy

Dr. Marco Tagliamento, Gustave Roussy, France
Project Title: The CHIC Study (Clonal Hematopoiesis In Lung Cancer)

Dr. Elena Torreggiani, University of Ferrara, Italy
Project Title: Dissecting the Role of Alpha-1 Antitrypsin in Malignant Pleural Mesothelioma Onset and Progression

2022 LCFA/BMS/ILCF DISPARITIES IN CLINICAL ONCOLOGY RESEARCH GRANTS

Dr. Jonathan Villena-Vargas, Weill Cornell Medicine, United States
Project Title: Characterizing T-Cell PD-1 Response in the Tumor Draining Lymph Nodes of Early-Stage NSCLC Patients

Dr. Amila Suraweera, Queensland University of Technology, Australia
Project Title: Development of a Novel Therapeutic for the Treatment of Non-Small Cell Lung Cancer

Dr. Anna Tek et al., The University of Sydney, Australia
Project Title: The Effect of Immune Checkpoint Inhibition on the Tumour Microenvironment in Non-Small Cell Lung Cancer

Dr. Elena Torreggiani, University of Ferrara, Italy
Project Title: Dissecting the Role of Alpha-1 Antitrypsin in Malignant Pleural Mesothelioma Onset and Progression

Dr. Marco Tagliamento, Gustave Roussy, France
Project Title: The CHIC Study (Clonal Hematopoiesis In Lung Cancer)

In 2022, the ILCF Board of Directors and the IASLC Board of Directors worked with a team of consultants to help determine the best way for the Foundation and its Research Grants Program to thrive now and in the future. The ILCF had operated as a separate legal entity, with a separate tax identification number, for several years. Beginning in 2023, the Research Grants Program will transition from the ILCF to the IASLC Foundation, LLC, a wholly-owned entity of the IASLC. Contributions to IASLC Foundation, LLC are treated as charitable contributions to a branch or division of IASLC. This change will provide streamlined operations and increased brand recognition to the Research Grants Program.
2022 ILCF DONORS

Donors are listed alphabetically by first/given name

TOP DONORS
Estate of Dr. Adi F. Gazdar ($1,152,500)
David and Diane Gandara ($10,000)
Be Your Possible, Inc. ($4,880)

INDIVIDUAL AND CORPORATE DONORS

$1,000-$2,999
Antoinette Wozniak
David Carbone
Greg Galanos
Jennifer Lamont
Karen Kelly
Lecia Sequist
REIOP, Inc.
Roy Herbst

$500-$999
Boris Borisov
Brendon Stiles
Erin Fitzgerald
Heather Wakelee
Jack Ruckdeschel
Lauren Fisher
Liza Hendriks
Maggie Connolly
Nadine Housri
Natasha Leighl

$100-$499
Aki Kobayashi
Alice Chen
Andre Moreira
Andrea Bezjak
Andrea Borondy Kitts
Angel Lopez-Galindo
Angela M Takano
Anita Archamety
Anne Traynor
Art Mallette
Balazs Halmos
Benjamin Solomon
Benson Vuong
Betty Tong
Bruce Dunbar
Caicun Zhou
Charles M Rudin
Corey Langer
Daniel Sterman
David Ball
David Gierada
David Harpole
David LeDuc
David Shames
David Stewart
Ebenezer Kio
Emanuel Citgez
Emily Stone
Eric Bernicker
Eric Sbar
Eric Vallieres
Erik Thunnissen
Etsuo Fujita
Eugene Paschold
Eugene Vissers
Eungbae Lee
Ferdinando Cerciello
Fiona Hegi-Johnson
Fred Hirsch
Glenn Lukos Associates, Inc.
Gregory M.M. Videtic
Gregory Raber
Helmut Prosch
Hiran Fernando
Hiromasa Yamamoto
Hossein Borghaei
Jacques Mascaro
James Chin-Hsin Yang
James Jett
Janet Piorko
Jasleen Pannu
Jason Porter
Jhanelle Gray
Joel Neal
John Hallick
John Minna
Joo-Hang Kim
Julie Brahmer
Jyoti Patel
Karen Reckamp
Katherine Sugarman
Kathryn Mileham
Kazuhiko Shibata
Keunchil Park
Konstantinos Leventakos
Leora Horn
Li Xu
Lisa Biggs
Louis Geeraerts
Luis Raez
Luka Brcic
Lynn & Greg Fricke
Lyudmila Bazhenova
Magnus Ulmoen
Makenzi Evangelist
Mallory Benjamin
Maria Amelia Almeida
Martin Edelman
Mary Jo Fidler
Masahiro Tsuboi
Matthew Yeingst
Matthijs Oudkerk
Mia Grane Jawdat
Michael Gieske
Michelle Brockman
Milada Zemanova
Ming Tsao
Misako Nagasaka
Miyaoko Satouchi
Neal Ready
Nichol Miller
Nico Van Zandwijk
Paul Hesketh
Paul Van Schil
Paul Walker
Qinghua Zhou
Rachel Sanborn
Rajwanth Veluswamy
Ricardo Salgado
Robert Pirker
Sergio Santillana
Sherry Baskerville-Bridges
Stephen Lam
Tao Feik Owonikoko
Ted Blank
Theresa LaVallee
Todd Sanft
Tom John
Turja Chakrabarti
Umberto Malapelle
Veronica Buckley
Vito Quaranta
Wade Iams
William Travis
William Walsh
Yasushi Yatabe
Yidan Qin
Young Tae Kim

$50-$99
Aaron Paolotto
Alessandra Anca Tudor
Alfredo Lopez
Andrew Eagle
Angus Pratt
Antonio Calles Blanco
Brian E Persing
Caitlin Enright
Calvin F Jones
Carlos Ferreira
Carol Peltzsch
Chi-Fu Jeff Yang
Chih Ole Nakaishi
Clarissa Baldotto
Desiree Hao
Drhuv Bansal
Dwight Owen
Eric Santoni-Rugi
Evan Osmundson
Georges Decker
Gerard J Fitzmaurice
Giovanni Selvaggi
Greg Otterson
Harvey Pass
Heidi Mulqueen
Heleno Freitas
Henriette Klein
Hideo Tsuchiya
Hiran Chishantha Fernando
Ida Meister
Ina Nordman
Jae Heun Chung
Jason Porter
Jeffrey Bradley
Jennifer Wing
Ji Yeon Kwon
Jimmie Ward
John Ferguson
John Mccann
John Skadow
Josh Sonett
Juan Carlos Vazquez Limon
Judy Johnson
Jules Derks
Katharine Rendle
Kathryn Engelhardt
Katie Redfield
Kentarou Nakagawa
Kert Sabbath
Donors are listed alphabetically by first/given name

<table>
<thead>
<tr>
<th>Donation Range</th>
<th>First/Given Name</th>
</tr>
</thead>
</table>
Donors are listed alphabetically by first/given name.

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lillian Leigh</td>
</tr>
<tr>
<td>Lindsay Pastore</td>
</tr>
<tr>
<td>Lindsay Thompson</td>
</tr>
<tr>
<td>Lisa Cruz</td>
</tr>
<tr>
<td>Louise Nott</td>
</tr>
<tr>
<td>Lucas Vitzthum</td>
</tr>
<tr>
<td>Lucia M Viola</td>
</tr>
<tr>
<td>Luigi Ventura</td>
</tr>
<tr>
<td>Luis Alberto Corales Rodriguez</td>
</tr>
<tr>
<td>Lynn Sametz</td>
</tr>
<tr>
<td>Marc de Perrot</td>
</tr>
<tr>
<td>Marcelo Corassa</td>
</tr>
<tr>
<td>Maria Gitto</td>
</tr>
<tr>
<td>Maria Lucia Reale</td>
</tr>
<tr>
<td>Maria Werner-Wasik</td>
</tr>
<tr>
<td>Mariana Petaccia de Macedo</td>
</tr>
<tr>
<td>Marianne Davies</td>
</tr>
<tr>
<td>Marjorie Deninger</td>
</tr>
<tr>
<td>Mark Woodcock</td>
</tr>
<tr>
<td>Mary Duffy</td>
</tr>
<tr>
<td>Mary Todd</td>
</tr>
<tr>
<td>Maryann Bradley</td>
</tr>
<tr>
<td>Masaya Yotsukura</td>
</tr>
<tr>
<td>Matt Presby</td>
</tr>
<tr>
<td>Matthew Belbasis</td>
</tr>
<tr>
<td>Matthew Smeltzer</td>
</tr>
<tr>
<td>Mauricio Pimentel</td>
</tr>
<tr>
<td>Maya Khalil</td>
</tr>
<tr>
<td>Megan Daly</td>
</tr>
<tr>
<td>Melissa Johnson</td>
</tr>
<tr>
<td>Melissa Neumann</td>
</tr>
<tr>
<td>Michael Boyer</td>
</tr>
<tr>
<td>Michaela Kirschner</td>
</tr>
<tr>
<td>Miltiadis Krokidis</td>
</tr>
<tr>
<td>Miriam Ceraolo</td>
</tr>
<tr>
<td>Nagashree Seetharamu</td>
</tr>
<tr>
<td>Nahida Islam</td>
</tr>
<tr>
<td>Naoko Shiraiwa</td>
</tr>
<tr>
<td>Nelson Ang</td>
</tr>
<tr>
<td>Nguyen Son Lam</td>
</tr>
<tr>
<td>Nina Helbekkmo</td>
</tr>
<tr>
<td>Noelia Aybar</td>
</tr>
<tr>
<td>Oleg Kshivets</td>
</tr>
<tr>
<td>Olga Valdman</td>
</tr>
<tr>
<td>Oliver Illini</td>
</tr>
<tr>
<td>Onyx Bengston</td>
</tr>
<tr>
<td>O’Ryan Jackson</td>
</tr>
<tr>
<td>Paul Cockrump</td>
</tr>
<tr>
<td>Paula Ugalde</td>
</tr>
<tr>
<td>Philippe Lebel</td>
</tr>
<tr>
<td>Pietro Bertoglio</td>
</tr>
<tr>
<td>Ping Hu</td>
</tr>
<tr>
<td>Prabhu Prasad</td>
</tr>
<tr>
<td>Rachelle Michie</td>
</tr>
<tr>
<td>Raghav Chandra</td>
</tr>
<tr>
<td>Rebecca Bunn</td>
</tr>
<tr>
<td>Reina Misono</td>
</tr>
<tr>
<td>Reiri Onodera</td>
</tr>
<tr>
<td>Renaud Whittom</td>
</tr>
<tr>
<td>Renee Parker</td>
</tr>
<tr>
<td>Renelle Myers</td>
</tr>
<tr>
<td>Rex Yung</td>
</tr>
<tr>
<td>Robert Kratzke</td>
</tr>
<tr>
<td>Rodrigo Sagastegui</td>
</tr>
<tr>
<td>Roman Yelensky</td>
</tr>
<tr>
<td>Roselle De Guzman</td>
</tr>
<tr>
<td>Ross Hair</td>
</tr>
<tr>
<td>Ryan Gentzler</td>
</tr>
<tr>
<td>Sameera Kumar</td>
</tr>
<tr>
<td>Samina Park</td>
</tr>
<tr>
<td>Sanford Hoffman</td>
</tr>
<tr>
<td>Sang-Yoon Lee</td>
</tr>
<tr>
<td>Sarah Wang</td>
</tr>
<tr>
<td>Sarah Weaver</td>
</tr>
<tr>
<td>Satoru Miura</td>
</tr>
<tr>
<td>Satoshi Hara</td>
</tr>
<tr>
<td>Satoshi Muto</td>
</tr>
<tr>
<td>Satoshi Shiono</td>
</tr>
<tr>
<td>Sayeda Yasmin-Karim</td>
</tr>
<tr>
<td>Seamus Cotter</td>
</tr>
<tr>
<td>Sebastian Peitzsch</td>
</tr>
<tr>
<td>Selda Samakoglu</td>
</tr>
<tr>
<td>Shanda Blackmon</td>
</tr>
<tr>
<td>Shannon Zhang</td>
</tr>
<tr>
<td>Shawn Butler</td>
</tr>
<tr>
<td>Shirley Hughes</td>
</tr>
<tr>
<td>Shota Nakamura</td>
</tr>
<tr>
<td>Signe Fransen</td>
</tr>
<tr>
<td>Simon Ekman</td>
</tr>
<tr>
<td>Simona Borilova</td>
</tr>
<tr>
<td>Soe Aung</td>
</tr>
<tr>
<td>Sofia Baka</td>
</tr>
<tr>
<td>Sonam Puri</td>
</tr>
<tr>
<td>Spasenija Savic Prince</td>
</tr>
<tr>
<td>Stefan Watzka</td>
</tr>
<tr>
<td>Stefano Cafarotti</td>
</tr>
<tr>
<td>Stephan Soder</td>
</tr>
<tr>
<td>Stephanie Valkaljan</td>
</tr>
<tr>
<td>Sujay Shah</td>
</tr>
<tr>
<td>Suman Shrestha</td>
</tr>
<tr>
<td>Sunhee Malinowski</td>
</tr>
<tr>
<td>Süreyya Sarhan</td>
</tr>
<tr>
<td>Suyog Jain</td>
</tr>
<tr>
<td>Sylvie Gaudet</td>
</tr>
<tr>
<td>Takaaki Sasaki</td>
</tr>
<tr>
<td>Tamas Molnar</td>
</tr>
<tr>
<td>Tanaka Fumihiro</td>
</tr>
<tr>
<td>Tania Alfaro</td>
</tr>
<tr>
<td>Taysser Sowley</td>
</tr>
<tr>
<td>Temple of Israel Religious School</td>
</tr>
<tr>
<td>Teresa Garcia-Manrique</td>
</tr>
<tr>
<td>Thomas Amoah</td>
</tr>
<tr>
<td>Tiffany English</td>
</tr>
<tr>
<td>Tina Cascone</td>
</tr>
<tr>
<td>Tindara Franchina</td>
</tr>
<tr>
<td>Todd Buchanan</td>
</tr>
<tr>
<td>Tom Wood</td>
</tr>
<tr>
<td>Tomma Hargraves</td>
</tr>
<tr>
<td>Tomohide Tamura</td>
</tr>
<tr>
<td>Toshiyuki Harada</td>
</tr>
<tr>
<td>Trevor Williams</td>
</tr>
<tr>
<td>Veni Ezhil</td>
</tr>
<tr>
<td>Vincent Fallet</td>
</tr>
<tr>
<td>Vinod Sharma</td>
</tr>
<tr>
<td>Viviane Alencar</td>
</tr>
<tr>
<td>Vladmir Horvat</td>
</tr>
<tr>
<td>Van-Sin Lim</td>
</tr>
<tr>
<td>Wei Wang</td>
</tr>
<tr>
<td>Weiqing Wang</td>
</tr>
<tr>
<td>Wendy Cooper</td>
</tr>
<tr>
<td>Wingfield Tan</td>
</tr>
<tr>
<td>Xiaokui Mo</td>
</tr>
<tr>
<td>Yao-Ming Shih</td>
</tr>
<tr>
<td>Yeon Wook Kim</td>
</tr>
<tr>
<td>Yeonsil Kim</td>
</tr>
<tr>
<td>Yewande Pearse</td>
</tr>
<tr>
<td>Yoshitaka Sekido</td>
</tr>
<tr>
<td>Youjin Oh</td>
</tr>
<tr>
<td>Younes El Founini</td>
</tr>
<tr>
<td>Yuki Matsumura</td>
</tr>
<tr>
<td>Yukihiro Yoshida</td>
</tr>
<tr>
<td>Yvette Thomas-Fogg</td>
</tr>
<tr>
<td>Zach Woolweaver</td>
</tr>
<tr>
<td>Zhirmin Zeng</td>
</tr>
</tbody>
</table>
## Financials

### December 31

<table>
<thead>
<tr>
<th></th>
<th>2022 (Unaudited)</th>
<th>2021 (Audited)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Program Revenues</strong></td>
<td>$17,725,947</td>
<td>$14,297,877</td>
</tr>
<tr>
<td><strong>Membership Revenues</strong></td>
<td>$673,597</td>
<td>$633,507</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td>$18,399,544</td>
<td>$14,931,384</td>
</tr>
<tr>
<td><strong>Direct Program Expenses</strong></td>
<td>$10,767,546</td>
<td>$9,576,707</td>
</tr>
<tr>
<td><strong>G&amp;A Expenses</strong></td>
<td>$6,257,671</td>
<td>$5,496,829</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$17,025,217</td>
<td>$15,073,536</td>
</tr>
<tr>
<td><strong>Operating Surplus</strong></td>
<td>$1,374,327</td>
<td>($142,152)</td>
</tr>
<tr>
<td><strong>Other Income (Loss)/Expense</strong></td>
<td>($1,410,258)</td>
<td>$1,171,478</td>
</tr>
</tbody>
</table>

### December 31

<table>
<thead>
<tr>
<th></th>
<th>2022 (Unaudited)</th>
<th>2021 (Audited)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td>$20,795,872</td>
<td>$21,306,201</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td>$6,374,917</td>
<td>$6,849,315</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td>$14,420,955</td>
<td>$14,456,886</td>
</tr>
</tbody>
</table>

### Revenue by Type

- Conferences & Meetings: 72%
- Scientific Projects: 12%
- Publications: 8%
- Membership: 4%
- Fellowships: 4%
IASLC STAFF

EXECUTIVE TEAM

Karen Kelly, MD
Chief Executive Officer

J. Michael Hoehn, CAE
Chief Operating Officer

John Skadow
Chief Financial Officer

Matt Yeingst, CFRE
Chief Development Officer

Tessa Baxter
ILC Foundation Coordinator, Project Manager

Becky Bunn
Senior Advisor, Scientific Relations

Mya Burns
Associate Director, Conferences

Casey Connolly
Scientific Affairs Specialist

Bailey Creamer
Editorial Assistant

Kathy Doherty
Director, Human Resources

Wanda Folsom
Education Manager

Rory Graham
Web Content Administrator

Ken Harrell
Member Records Administrator

Kelsey Hecker
Conference Coordinator

Kelly Heemsbergen
Conference Manager

O’Ryan Jackson
Administrative Assistant

Vun-Sin Lim, PhD
Editorial Consultant, JTO Clinical and Research Report

Sara Lindsey Patton
Patient Advocacy Specialist

Katie Maher
Member Experience Specialist

STAFF
STAFF CONTINUED

Sunhee Malinowski
Accounting Manager

Jan Mazotti
Associate Director, Marketing & Communications

Karen Muth
Executive Assistant and Board Liaison

Kelly Nevins
Associate Director, Education

Rodrigo Sagastegui
Marketing Specialist

Kelsey Wood
Associate Director, Member Experience

Kelly Wright
Member Experience Coordinator

Murry Wynes, PhD
Senior Advisor, Scientific Affairs

Kexin Yu
Accountant

Flavia Zarcula
Corporate Relations Manager